External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ESH-CART 2025
Roche and Genentech at

ESH-CART 2025

September 26 - September 28
Stockholm, Sweden
esh.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:55 PM
Duration 35mins Stockholm, Sweden
Efficacy and safety of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma after 1 or ≥2 prior lines of therapy
Dr Charles Herbaux
Haematology - Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.